Welcome to MolDiag-PaCa
Principal investigator
Jens Peter von Kries, Ph.D.
Tel.: 0049-30-9406-2982
Fax:                           -2922
Mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Web: fmp-berlin.de/kries

Participants of the group:
Christoph Erdmann, TA
Tel.: 0049-30-9406-2909

The Screening-Unit will be engaged in the search for and experimental characterization of small molecules which decorate pancreatic tumor antigens. In vitro assay suitable for high-throughput screening of the small molecule libraries of the FMP will be established in pilot screens.


The Screening-Unit of the FMP serves the central compound library of the german initiative for Chemical Biology (for details see http://www.chembionet.de). The library has been designed after analysis of the world drug index for privileged subscaffolds and selection of a structural diversity set of 17.000 compounds, which represents the chemical space of the WDI. This unique library has been set up in collaboration of the FMP with ChemDiv. and co-financed by the Max-Delbrueck-Center (MDC,Berlin) and the Gesellschaft f?technologische Forschung (GBF, Braunschweig). The ChemBioNet library also contains additional 4.000 compounds spent by chemists of the network. Screening and chemical data are combined in the central database of the ChemBioNet. In total the compound libraries of the FMP comprise more then 40.000 small molecules within sublibraries of the NIH, the natural product pool of the Hans-Knoell-Institute (HKI, Jena) and compounds synthesized by the medicinal chemistry group of the FMP.

Furthermore the screening unit of the FMP will set up assays for targets provided or identified by the subprojects. In this specific collaboration the screening unit will serve as facility for the identification of compounds which decorate specific pancreatic tumor antigens by automated screens of  compound libraries.

ChemBioNet Library:

The compound collection (17951 compounds) has been designed after analysis of the "World Drug Index, WDI" for privileged substructures or scaffolds by the drug design and modeling group of the "Leibniz-Institut für Molekulare Pharmakologie". The library is placed on 384-well microtiter plates with compounds solubilized at 10 mM concentrations in DMSO (created by ChemDiv). The last two columns of each plate contain only DMSO for set up of controls on the assay plates.

The library contains also about 1000 compounds from the international LOPAC collection of annotated compounds (provided by Sigma Aldrich).

The library is shared with the Leibniz-Institut für Molekulare Pharmakologie (FMP, Berlin), the Helmholtz-Zentrum für Infektionsforschung (former GBF, Braunschweig), the Max-Delbr?ntrum (MDC, Berlin) and the Max-Planck-Institut für Molekulare Physiologie (MPI, Dortmund). The library is cofinanced by FMP, GBF and MDC.

ChemBioNet 384-well Format

Compounds sequentially placed from A1 to P1 (1-16) with increasing numbers from top to bottom and left to right columns. Columns 23 and 24 contain DMSO for set up of controls after transfer of compounds to test plates.

Note that the format of the fragment library (FMP57, 20.000) differs in position of DMSO loaded columns
(column 1 and column 24)!!!


Teaching course on the pathology of pancreatic tumors
in Verona, May 18th 2007

In the last few years, new concepts regarding the histological and molecular subclassification of exocrine pancreatic tumors have been established. This short course, organized by experts in the field from the Pathology Departments at the Universities of Verona (Italy) and Kiel (Germany) as well as the Fundació IMIM, Barcelona (Spain), aims at providing a review of these advances and an update wih as much an emphasis in the pathological aspects as in the molecular alterations specifically associated with each tumor type. The short course is addressed to non-specialists who wish to keep abreast of pancreatic cancer molecular pathology.

The course will cover the following program:

9:00 Where does the pancreas come from?    
Cell lineage markers of the pancreas
Francisco X. Real, Fundació IMIM, Barcelona, Spain

9:35 Ductal adenocarcinoma
Günther Klöppel, University Hospital Schleswig-Holstein, Kiel, Germany

10:10 Ductal type neoplasms
Giuseppe Zamboni, University of Verona, Italy

10:45 Coffee Break

11:15 Non-ductal type neoplasms
Bence Sipos, University Hospital Schleswig-Holstein, Kiel, Germany

11:50 Pheno/genotype correlations
Aldo Scarpa, University of Verona, Italy


For more details, please contact:
Prof. Aldo Scarpa
Dipartimento di Patologia
Università di Verona
Strada Le Grazie, 8
37134  Verona, Italia

Tel. +39-045-8124.043
Fax. +39-045-8027.136
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Participation is free of cost.
Cost for accommodation and travel will have to be covered by the participants.

>> Publications

Professor Thomas M. Gress is the coordinator of the MolDiag-Paca consortium.

Overall research programme:
Our group has used array/microarray technology for the past 13 years for expression and genomic profiling analyses of gastrointestinal tumours. Our major aim is the characterization of genetic profiles of pancreatic tumours as a basis to develop novel diagnostic and therapeutic tools.

Role in the Integrated Project:
Apart from the managing role we will coordinate WP 3, and will perform a major part of the work planned therein. This will include the generation and design of diagnostic approaches based on RNA analyses of single genes and/or on diagnostic microarrays.

Group members:
  • Dr. Malte Buchholz (Key person 2)
  • PD Dr. Volker Ellenrieder
  • Dr. Hans Kestler
  • Dr. Heiko Fensterer
  • Dr. Patrick Michl
  • Dr. Steffen Kunsch
  • Anja Gruner
  • Johannes Huth
  • Dr. Björg Pauling
  • Esther Buchholz

Baldingerstraße, 35043 Marburg
Telefon (06421) 58 66459 / 58 66460
Telefax: (06421) 58 68922
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Name: Thomas Mathias Gress
Birth: 11.10.62
Birthplace: Sao Paulo/Brasil


1981 - 1987
Study of Medicine at the Philipps-Universität Marburg/Germany
1987 - 1996
Scientific and clinical assistant departments of pediatrics and gastroenterology (Heidelberg, Marburg and Ulm)
1989 - 1991
Postdoctoral fellow at the Institute of Human Genetics (Philipps-Universität Marburg/Germany) and at the Imperial Cancer Research Fund (Genome Analysis Laboratory) in London/UK
1998 - 2001
Heisenberg-Fellow of the DFG
2001 - 2006
Full professor for Gastroenterology at the University of Ulm
since 01.02.2006
Chair of Gastroenterology and Endocrinology, Department of Internal Medicine, Philipps-Universität Marburg, Germany

Board certifications/diplomas:
Internal Medicine (1996), Gastroenterology (1999), Diabetology (DDG, 2003), oncological Gastroenterology (DGVS, 2004), Diploma in Health economy (2004)

Membership in Associations/Boards:
  • German Society for Gastroenterology 1993-
  • American Association for Cancer Research 1995-
  • European Association for Research and Treatment of Cancer (EORTC) 1994-
  • American Association for Gastroenterology 1997-
  • German Cancer Society 1998-
  • European Society of Medical Oncology (ESMO) 6.99-
  • German Pancreatic Club 06.2004-
  • International Pancreatic Association 06.2004-
  • European Pancreatic Club 06.2004-

>> Publications

Dr. Jörg Hoheisel

is head of the Division of Functional Genome Analysis at DKFZ.
Dr. Andrea Bauer
is coordinating the activities in the area of pancreatic cancer.

Overall research programme:
Research at the Division of Functional Genome Analysis (www.dkfz.de/funct_genome) aims at the development and immediate application of new technologies for the production and processing of molecular information at a global cellular level. The overall objectives are an analysis, assessment and description of the realisation of cellular function from genetic information as well as the understanding of the regulation of the relevant processes. Many projects are pursued in national and international collaborations and programmes.

One emphasis area in our efforts is work on DNA-, protein- and peptide-microarrays. Many chemical and biophysical issues as well as matters of data analysis are being addressed in an attempt to understand the underlying procedural aspects, thereby eventually establishing superior analysis procedures. Based on the technical advances, the methods are immediately put to use in several, biologically or biomedically motivated studies of various kinds on different organisms. Concerning the analysis of human material, systems are being developed toward early diagnosis, prognosis and evaluation of the success of disease treatment with an accentuation on cancer.

Comparative studies are under way, for instance, on the epigenetic modulation of the genome, in combination with transcription factor binding assays, measurements of transcript levels and the actual protein expression, the last performed by means of complex antibody microarrays, toward an understanding of biological functions and their cellular consequences. To this end, also new methods and tools are required, such as for the selection of antibodies of high specificity and affinity. Another area of activity is the establishment of processes for studies on the influence of DNA-structure on enzymatic activities. This direction of research has perspectives for both analytical purposes and towards a basic scientific understanding of interactions of protein and nucleic acids. Genomic mapping and sequencing is still an area of activity, although of ever decreasing importance; such projects are only performed as preparation for subsequent functional analyses.

Another line of work aims at a combination of both the technical advances and the global biological information obtained from genomic approaches. From this knowledge base, complex experimental in vitro processes are implemented. One motivation is their utilisation in synthetic biology activities for the production of molecules and the establishment of molcular systems. Cell-free biosynthetic production will become important for many biotechnological and pharmacochemical challenges ahead. The complex experimental molecular systems are meant to complement current systems-biology. By means of such in vitro systems, biological models can be evaluated experimentally. Similar to physics, insight into cellular functioning will be gained by an iterative processing of information by experimental and theoretical systems-biology. Eventually, this may lead to the establishment of an archetypical model of a cell.

Apart from publications in scientific journals, the division filed a large number of patent applications, of which quite a few have been licensed out or are utilised in ongoing collaborations with commercial partners.

Role in the Integrated Project:
We are coordinating WP5 (Epigenetic analyses) and are involved in three other workpackages (RNA, protein, imaging).

Group members involved:
  • Dr. Michaela Schanne
  • Dr. Neeme Tonisson
  • Dr. Kurt Fellenberg
  • Anette Boerner
  • Hans-Peter Maser
  • Christoph Schröder
  • Melanie Bier

Functional Genome Analysis, Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany
Telefon:  +49-6221-424882
Telefax:   +49-6221-424687
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.